Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54,731,500
-
Total 13F shares
-
28,625,188
-
Share change
-
-1,019,946
-
Total reported value
-
$139,757,658
-
Put/Call ratio
-
116%
-
Price per share
-
$4.84
-
Number of holders
-
63
-
Value change
-
-$7,031,843
-
Number of buys
-
25
-
Number of sells
-
45
Institutional Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q2 2022
As of 30 Jun 2022,
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) was held by
63 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,625,188 shares.
The largest 10 holders included
Lion Point Capital, LP, SUVRETTA CAPITAL MANAGEMENT, LLC, VR Adviser, LLC, Avoro Capital Advisors LLC, 683 Capital Management, LLC, VANGUARD GROUP INC, Bain Capital Life Sciences Investors, LLC, Bleichroeder LP, ADAGE CAPITAL PARTNERS GP, L.L.C., and Artal Group S.A..
This page lists
63
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.